Urinary analgesics
This article was originally published in The Tan Sheet
Executive Summary
The availability of OTC urinary tract infection diagnostic kits in conjunction with the condition's "readily recognizable symptoms" combines to create a safe atmosphere for self-medication using phenazopyridine hydrochloride, Polymedica Pharmaceuticals maintains in recent comments filed with FDA. Current labeling requirements "are sufficient to ensure safe and effective" OTC consumer use of the ingredient, the Azo Standard marketer says. OTC urinary analgesic products "clearly instruct the consumer to seek appropriate medical attention if symptoms persist beyond a specific time," the firm adds, echoing separate comments filed by CHPA (1"The Tan Sheet" July 12, 2004, p. 6)...
You may also be interested in...
Urinary Analgesics’ Safe History Justifies Monograph Inclusion – CHPA
Urinary analgesic products' safe history of use in an over-the-counter setting support the establishment of an OTC monograph, the Consumer Health Products Association maintains in June 28 comments to FDA
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.